AstraZeneca updates total voting rights for June 2026

AstraZeneca PLC has updated investors on its share capital and voting rights.

Rhea-AI Filing Summary

AstraZeneca PLC has updated investors on its share capital and voting rights. As at 30 June 2026, the company had 1,551,024,534 ordinary shares of US$0.25 each in issue, all carrying voting rights. No shares are held in treasury, so the total number of voting rights is 1,551,024,534. Shareholders can use this figure as the denominator when calculating whether they must notify holdings or changes in holdings under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

Key Figures

Total voting rights: 1,551,024,534 Issued ordinary shares: 1,551,024,534 shares Par value per share: US$0.25 per share

3 metrics

Total voting rights 1,551,024,534 Total number of voting rights as at 30 June 2026

Issued ordinary shares 1,551,024,534 shares Issued share capital with voting rights as at 30 June 2026

Par value per share US$0.25 per share Nominal value of AstraZeneca PLC ordinary shares

Key Terms

Total Voting Rights, Disclosure and Transparency Rule 5.6.1, issued share capital, Treasury, +1 more

5 terms

Total Voting Rights financial

"1 July 2026 Total Voting Rights The following notification is made..."

The total voting rights number is the count of shares that carry the right to vote at a company’s shareholder meetings, reflecting how much voting power exists in the market. Investors use it to understand control and influence—like knowing how many votes are in play when measuring ownership stakes, calculating a shareholder’s voting percentage, or assessing how easy it would be for a holder to sway decisions.

Disclosure and Transparency Rule 5.6.1 regulatory

"The following notification is made in accordance with the Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1."

issued share capital financial

"As at 30 June 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,024,534 ordinary shares..."

Issued share capital is the total value or number of a company's shares that have been created and given to investors, employees or others; think of it as the slices of a cake that have already been cut and distributed. It matters to investors because it determines ownership percentages, potential voting power and how future share sales can dilute existing holdings, affecting share value and control.

Treasury financial

"No shares are held in Treasury."

The treasury is the department or area within a government or organization responsible for managing its money, finances, and financial strategies. It handles tasks like collecting revenue, paying bills, and planning for future financial needs, much like a household manages its budget. For investors, understanding the treasury is important because it influences interest rates, government spending, and overall economic stability.

voting rights financial

"Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,024,534."

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What total voting rights did AstraZeneca (AZN) report as of 30 June 2026?

AstraZeneca reported 1,551,024,534 total voting rights as of 30 June 2026. This equals its entire issued share capital of ordinary shares, since no shares are held in treasury, and is used by shareholders for regulatory notification thresholds.

How many AstraZeneca (AZN) ordinary shares are in issue and carry voting rights?

AstraZeneca has 1,551,024,534 ordinary shares of US$0.25 each in issue, all with voting rights. The company holds no treasury shares, so every issued share contributes one vote in shareholder decision-making processes and regulatory ownership calculations.

Does AstraZeneca (AZN) hold any of its shares in treasury according to this 6-K?

AstraZeneca states that no shares are held in Treasury as of 30 June 2026. This means the entire issued share capital of 1,551,024,534 ordinary shares counts toward total voting rights and shareholder ownership calculations under FCA rules.

Why is AstraZeneca’s (AZN) total voting rights figure important for shareholders?

The total voting rights figure is the denominator shareholders use to calculate ownership percentages. AstraZeneca explains that investors rely on the 1,551,024,534 voting rights to determine whether they must notify interests or changes under UK Disclosure and Transparency Rules.

Which regulatory rule governs AstraZeneca’s (AZN) total voting rights notification?

The notification is made under the UK Financial Conduct Authority’s Disclosure and Transparency Rule 5.6.1. AstraZeneca uses this rule framework to inform the market about its issued share capital and voting rights position as at 30 June 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/01/2026 - 10:06 AM EDT Learn about SEC filing dates

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of July 2026 

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Total Voting Rights

1 July 2026

Total Voting Rights

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 30 June 2026 the issued share capital of AstraZeneca PLC with voting rights is 1,551,024,534 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,551,024,534.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Disease, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Social Media @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Matthew Bowden

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 July 2026

By: /s/ Matthew Bowden

Name: Matthew Bowden

Title: Company Secretary